Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pantothenol→

Pantothenol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
81-13-0
Molecular formula
C9H19NO4
Molecular weight
205.25 g/mol
Drug class
Provitamin B5dexpanthenol-related skin-conditioning and wound-care agent
Mechanism of action
An alcoholic analogue of D-pantothenic acid that is converted to pantothenic acid and contributes to coenzyme A synthesis. Topical dexpanthenol-containing preparations support skin hydration and epithelial repair; the exact mechanism in topical use is not fully established.
Indications / reported uses
  • Topical use to support skin-barrier recovery and minor wound healing in authorised creams and ointments.
  • Dexpanthenol-containing preparations are also used for selected mucosal and gastrointestinal indications in some jurisdictions.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/dexpanthenol · https://pubchem.ncbi.nlm.nih.gov/#query=pantothenol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pantothenol Environmental Risk Assessment (ERA) (the Pantothenol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.